Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype (ConNic3)

This study has been completed.
Sponsor:
Collaborator:
Philip Morris USA, Inc.
Information provided by (Responsible Party):
Duke University
ClinicalTrials.gov Identifier:
NCT00894166
First received: May 4, 2009
Last updated: September 19, 2013
Last verified: September 2013
  Purpose

Nicotine replacement therapy (NRT) is a well-tolerated and efficacious smoking cessation treatment, and yet many smokers fail to quit using NRT. Many of these smokers may benefit from prescription treatment alternatives, including Zyban or Chantix. In this study, the investigators propose to develop and evaluate a stepped-care treatment algorithm that would evaluate whether smokers who receive treatment with NRT should be supplemented with Zyban or switched to Chantix only based on: 1) their initial response to NRT; and 2) individual genetic factors found to predict smoking cessation in other studies evaluating these treatments. This study is a continuation of our previous studies showing that abstinence rates can be increased by starting nicotine patch therapy two weeks before the quit date. The investigators will provide pre-cessation NRT to all participants initially. Those who do not show a favorable response on early indicators of success (e.g., smoking in the first week after the target quit-smoking date) will receive "rescue" treatment by having their NRT treatment supplemented with Zyban , by being switched to treatment with Chantix or will remain on NRT (control).

The investigators hypothesize that "Rescue" treatment with Zyban in combination with NRT or Chantix will increase success rates over leaving subjects on NRT when they are NRT insufficient responders, i.e. they have shown an unfavorable response to NRT in the first week pre-quit or the first week post-quit.


Condition Intervention Phase
Smoking Cessation
Drug: Nicotine Patches
Drug: Nicotine patches, then bupropion & nicotine patches (Pre-Quit)
Drug: Nicotine patches, then varenicline (Pre-Quit)
Drug: Nicotine patches, then nicotine patches (Pre-Quit)
Drug: Nicotine patches, then bupropion & nicotine patches (Post-Quit)
Drug: Nicotine patches, then varenicline (Post-Quit)
Drug: Nicotine patches, then nicotine patches (Post-Quit)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Official Title: Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype

Resource links provided by NLM:


Further study details as provided by Duke University:

Primary Outcome Measures:
  • Continuous 4-week Abstinence From Smoking Between Weeks 8-11 After the Quit Date (Through the End of Treatment) [ Time Frame: weeks 8-11 after quit date ] [ Designated as safety issue: No ]
    A self report of no cigarettes smoked confirmed by expired air carbon monoxide of <=10ppm was the criterion for abstinence.


Secondary Outcome Measures:
  • Abstinence (7 Days) at 6 Months. [ Time Frame: point abstinence (7 days) at 6 months post-quit date ] [ Designated as safety issue: No ]
  • Continuous Abstinence From Smoking at 6 Months Post Quit. [ Time Frame: continuous abstinence at 6 months post quit day ] [ Designated as safety issue: No ]

Enrollment: 606
Study Start Date: May 2009
Study Completion Date: October 2011
Primary Completion Date: July 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Nicotine Replacement Therapy Responder
Nicotine Responders
Drug: Nicotine Patches
21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
Other Name: NicoDermCQ
Active Comparator: Pre-Quit Rescue to Bupropion & Nicotine
Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Zyban (bupropion) in combination with nicotine patches
Drug: Nicotine patches, then bupropion & nicotine patches (Pre-Quit)
21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
Other Names:
  • Zyban
  • NicoDermCQ
Active Comparator: Pre-Quit Rescue to Varenicline
Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Chantix (varenicline)
Drug: Nicotine patches, then varenicline (Pre-Quit)
21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
Other Names:
  • Chantix
  • NicoDermCQ
Active Comparator: Pre-Quit Rescue to Nicotine
Participants not responsive to nicotine patches who are randomly assigned at week 2 to continued use of nicotine patches
Drug: Nicotine patches, then nicotine patches (Pre-Quit)
21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
Other Name: NicoDermCQ
Active Comparator: Post-Quit Rescue to Bupropion & Nicotine
Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Zyban (bupropion) in combination with nicotine patches
Drug: Nicotine patches, then bupropion & nicotine patches (Post-Quit)
21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
Other Names:
  • Zyban
  • NicoDermCQ
Active Comparator: Post-Quit Rescue to Varenicline
Participants not responsive to nicotine patches who are randomly assigned at week 4 to use of Chantix (varenicline)
Drug: Nicotine patches, then varenicline (Post-Quit)
21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
Other Names:
  • Chantix
  • NicoDermCQ
Active Comparator: Post-Quit Rescue to Nicotine
Participants not responsive to nicotine patches who are randomly assigned at week 4 to continued use of nicotine patches
Drug: Nicotine patches, then nicotine patches (Post-Quit)
21mg (1 patch) or 42mg (2 patches) nicotine patches for first seven weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
Other Name: NicoDermCQ

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18-65 years old
  • smoked an average of at least 10 cigarettes per day for three cumulative years of a brand that delivers (by Federal Trade Commission rated yields) at least 0.5mg nicotine
  • expired carbon monoxide reading of at least 15ppm
  • express a desire to quit smoking in the next 30 days

Exclusion Criteria:

  • Hypertension (systolic >140 mm Hg, diastolic >100 mm Hg, coupled with a history of hypertension); subjects with no previous diagnosis of hypertension may have a screening blood pressure up to 160/100.
  • Hypotension (systolic <90 mm Hg, diastolic <60 mm Hg).
  • Participants with a history of hypertension may, however, be allowed to participate in the study if the study physician or physician assistant determines that the condition is stable, controlled by medication, and in no way jeopardizes the individual's safety.
  • Coronary heart disease;
  • Lifetime history of heart attack;
  • Cardiac rhythm disorder (irregular heart rhythm);
  • Chest pains (unless history, exam, and ECG clearly indicate a non-cardiac source);
  • Cardiac (heart) disorder (including but not limited to valvular heart disease, heart murmur, heart failure);
  • History of skin allergy;
  • Active skin disorder (e.g., psoriasis) within the last five years, except minor skin conditions (including but not limited to facial acne, minor localized infections, and superficial minor wounds);
  • Liver or kidney disorder (except kidney stones, gallstones);
  • Gastrointestinal problems or disease other than gastroesophageal reflux or heartburn;
  • Active ulcers in the past 30 days;
  • Lung disorder (including but not limited to Chronic obstructive pulmonary disease (COPD), emphysema, and asthma);
  • Brain abnormality (including but not limited to stroke, brain tumor, and seizure disorder);
  • History of migraine headaches in the past 5 years;
  • History of fainting;
  • Problems giving blood samples;
  • Diabetes treated with insulin; non-insulin treated diabetes (unless glucose is less than 180mg/dcl and HbA1c is less than 7%);
  • Current cancer or treatment for cancer in the past six months (except basal or squamous cell skin cancer);
  • Other major medical condition;
  • Current psychiatric disease (with the exception of anxiety disorders, Obsessive-compulsive disorder (OCD) and ADHD);
  • Suicidal ideation (within the past 10 years) or lifetime occurrence of attempted suicide;
  • Current depression - The Patient Health Questionnaire (PHQ-9) for Depression will be used to screen for current (within 2 weeks) depression. Potential subjects who score >9 (or who score >0 on item #9 ("Thoughts that you would be better off dead, or of hurting yourself in some way") will be excluded from study participation, and, at the discretion of the study physician, referred to appropriate psychiatric treatment;
  • Bulimia or anorexia;
  • Pregnant or nursing mothers;
  • Use (within the past 30 days) of:
  • Illegal drugs (or if the urine drug screen is positive),
  • Experimental (investigational) drugs;
  • Psychiatric medications including antidepressants, anti-psychotics or any other medications that are known to affect smoking cessation (e.g. clonidine);
  • Opiate medications for pain or sleep (non-opiate medication for pain or sleep will be allowed)
  • Smokeless tobacco (chewing tobacco, snuff), cigars or pipes;
  • Wellbutrin, bupropion, Zyban, Chantix, nicotine replacement therapy or any other smoking cessation aid.
  • Alcohol abuse - The AUDIT (Alcohol Use Disorders Identification Test) questionnaire will be used to assess alcohol abuse. Potential participants will be asked the first two questions on the AUDIT questionnaire during the phone screen. If the person scores "4" on both questions, a screening appointment will not be scheduled. During the screening session the entire AUDIT questionnaire will be administered. Females who score greater than or equal to 13 and males who score greater than or equal to 15 will be excluded from the study.
  • Significant adverse reaction to Wellbutrin / Zyban or Chantix / Varenicline in the past
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00894166

Locations
United States, North Carolina
Duke Center for Nicotine & Smoking Cessation Research
Charlotte, Durham, Raleigh, Winston-Salem, North Carolina, United States
Sponsors and Collaborators
Duke University
Philip Morris USA, Inc.
Investigators
Principal Investigator: Jed E Rose, Ph.D. Duke University
  More Information

No publications provided by Duke University

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Duke University
ClinicalTrials.gov Identifier: NCT00894166     History of Changes
Other Study ID Numbers: Pro00013846
Study First Received: May 4, 2009
Results First Received: October 19, 2012
Last Updated: September 19, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Duke University:
Smoking Cessation
Chantix
varenicline
Nicotine Replacement Therapy
Nicotine Patches
Zyban
bupropion
Quit Smoking

Additional relevant MeSH terms:
Nicotine
Varenicline
Bupropion
Ganglionic Stimulants
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions
Nicotinic Agonists
Cholinergic Agonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Uptake Inhibitors

ClinicalTrials.gov processed this record on August 28, 2014